Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Btc Corporation is managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and 1 distinct art unit. The current prosecution effort is entirely focused on this single active case. With 1 pending office action, the applicant can concentrate their legal strategy on a single set of examiner requirements.
CREWS, JARET JAMES is the busiest examiner, holding the 1 pending office action. With 1 distinct examiner and 1 distinct art unit, the applicant's success in this area depends on the specific review of this individual. This 1 to 1 ratio between pending actions and examiners allows for a concentrated prosecution strategy, as there are no other active matters to coordinate within the Biotechnology & Pharmaceuticals sector. The presence of 1 distinct art unit means that the technology is being evaluated by a single specialized department at the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CREWS, JARET JAMES | 1 | 43.9% | +71.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18724442 | COMPOSITION FOR IMPROVING EXERCISE PERFORMANCE COMPRISING GYPENOSIDE COMPOUND AS ACTIVE INGREDIENT | CREWS, JARET JAMES | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18724442 | COMPOSITION FOR IMPROVING EXERCISE PERFORMANCE COMPRISING GYPENOSIDE COMPOUND AS ACTIVE INGREDIENT | CREWS, JARET JAMES | 1691 | §102§112DP | Non-Final OA | — | Pending | Jun 26, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBtc Corporation has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jaret James Crews has the most, with 1 of Btc Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
